CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Service
4.2. Immune Boosters
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Energy Boosters
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Skin Care
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Migraine
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT
5.1. Market Overview
5.1.1 Market Size and Forecast, By Component
5.2. Medicated
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Non-medicated
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospital Clinics
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Wellness Centers Spas
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Home Healthcare
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Service
7.2.3. Market Size and Forecast, By Component
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Intravenous (IV) Hydration Therapy Market
7.2.6.1. Market Size and Forecast, By Service
7.2.6.2. Market Size and Forecast, By Component
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Intravenous (IV) Hydration Therapy Market
7.2.7.1. Market Size and Forecast, By Service
7.2.7.2. Market Size and Forecast, By Component
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Intravenous (IV) Hydration Therapy Market
7.2.8.1. Market Size and Forecast, By Service
7.2.8.2. Market Size and Forecast, By Component
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Service
7.3.3. Market Size and Forecast, By Component
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. France Intravenous (IV) Hydration Therapy Market
7.3.6.1. Market Size and Forecast, By Service
7.3.6.2. Market Size and Forecast, By Component
7.3.6.3. Market Size and Forecast, By End User
7.3.7. Germany Intravenous (IV) Hydration Therapy Market
7.3.7.1. Market Size and Forecast, By Service
7.3.7.2. Market Size and Forecast, By Component
7.3.7.3. Market Size and Forecast, By End User
7.3.8. Italy Intravenous (IV) Hydration Therapy Market
7.3.8.1. Market Size and Forecast, By Service
7.3.8.2. Market Size and Forecast, By Component
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Spain Intravenous (IV) Hydration Therapy Market
7.3.9.1. Market Size and Forecast, By Service
7.3.9.2. Market Size and Forecast, By Component
7.3.9.3. Market Size and Forecast, By End User
7.3.10. UK Intravenous (IV) Hydration Therapy Market
7.3.10.1. Market Size and Forecast, By Service
7.3.10.2. Market Size and Forecast, By Component
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest Of Europe Intravenous (IV) Hydration Therapy Market
7.3.11.1. Market Size and Forecast, By Service
7.3.11.2. Market Size and Forecast, By Component
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Service
7.4.3. Market Size and Forecast, By Component
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. China Intravenous (IV) Hydration Therapy Market
7.4.6.1. Market Size and Forecast, By Service
7.4.6.2. Market Size and Forecast, By Component
7.4.6.3. Market Size and Forecast, By End User
7.4.7. Japan Intravenous (IV) Hydration Therapy Market
7.4.7.1. Market Size and Forecast, By Service
7.4.7.2. Market Size and Forecast, By Component
7.4.7.3. Market Size and Forecast, By End User
7.4.8. India Intravenous (IV) Hydration Therapy Market
7.4.8.1. Market Size and Forecast, By Service
7.4.8.2. Market Size and Forecast, By Component
7.4.8.3. Market Size and Forecast, By End User
7.4.9. South Korea Intravenous (IV) Hydration Therapy Market
7.4.9.1. Market Size and Forecast, By Service
7.4.9.2. Market Size and Forecast, By Component
7.4.9.3. Market Size and Forecast, By End User
7.4.10. Australia Intravenous (IV) Hydration Therapy Market
7.4.10.1. Market Size and Forecast, By Service
7.4.10.2. Market Size and Forecast, By Component
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy Market
7.4.11.1. Market Size and Forecast, By Service
7.4.11.2. Market Size and Forecast, By Component
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Service
7.5.3. Market Size and Forecast, By Component
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Intravenous (IV) Hydration Therapy Market
7.5.6.1. Market Size and Forecast, By Service
7.5.6.2. Market Size and Forecast, By Component
7.5.6.3. Market Size and Forecast, By End User
7.5.7. South Africa Intravenous (IV) Hydration Therapy Market
7.5.7.1. Market Size and Forecast, By Service
7.5.7.2. Market Size and Forecast, By Component
7.5.7.3. Market Size and Forecast, By End User
7.5.8. Saudi Arabia Intravenous (IV) Hydration Therapy Market
7.5.8.1. Market Size and Forecast, By Service
7.5.8.2. Market Size and Forecast, By Component
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Intravenous (IV) Hydration Therapy Market
7.5.9.1. Market Size and Forecast, By Service
7.5.9.2. Market Size and Forecast, By Component
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Davita
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Nikkiso Co. Ltd.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Core IV Therapy, LLC
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Cryojuvenate UK Ltd.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. B. Braun Medical Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Otsuka Pharmaceutical Co., Ltd.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. NexGen Health
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. JW Life Science Corporation
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Amanta Healthcare Limited.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Baxter International Inc.?
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 2. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 8. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 11. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 20. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 21. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 22. U.S. INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 24. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 25. CANADA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 28. MEXICO INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 32. EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 35. FRANCE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 37. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 38. GERMANY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 39. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 40. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 41. ITALY INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 43. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 44. SPAIN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 45. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 46. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 47. UK INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 50. REST OF EUROPE INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 54. ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 56. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 57. CHINA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 59. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 60. JAPAN INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 61. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 62. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 63. INDIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 65. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 66. SOUTH KOREA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 68. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 69. AUSTRALIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 72. REST OF ASIA-PACIFIC INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 76. LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 79. BRAZIL INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 80. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 81. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 82. SOUTH AFRICA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 84. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 85. SAUDI ARABIA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY SERVICE, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY COMPONENT, 2024 - 2033 ($BILLION)
TABLE 88. REST OF LAMEA INTRAVENOUS (IV) HYDRATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 89. DAVITA: KEY EXECUTIVES
TABLE 90. DAVITA: COMPANY SNAPSHOT
TABLE 91. DAVITA: OPERATING SEGMENTS
TABLE 92. DAVITA: PRODUCT PORTFOLIO
TABLE 93. DAVITA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. NIKKISO CO. LTD.: KEY EXECUTIVES
TABLE 95. NIKKISO CO. LTD.: COMPANY SNAPSHOT
TABLE 96. NIKKISO CO. LTD.: OPERATING SEGMENTS
TABLE 97. NIKKISO CO. LTD.: PRODUCT PORTFOLIO
TABLE 98. NIKKISO CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. CORE IV THERAPY, LLC: KEY EXECUTIVES
TABLE 100. CORE IV THERAPY, LLC: COMPANY SNAPSHOT
TABLE 101. CORE IV THERAPY, LLC: OPERATING SEGMENTS
TABLE 102. CORE IV THERAPY, LLC: PRODUCT PORTFOLIO
TABLE 103. CORE IV THERAPY, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. CRYOJUVENATE UK LTD.: KEY EXECUTIVES
TABLE 105. CRYOJUVENATE UK LTD.: COMPANY SNAPSHOT
TABLE 106. CRYOJUVENATE UK LTD.: OPERATING SEGMENTS
TABLE 107. CRYOJUVENATE UK LTD.: PRODUCT PORTFOLIO
TABLE 108. CRYOJUVENATE UK LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. B. BRAUN MEDICAL INC.: KEY EXECUTIVES
TABLE 110. B. BRAUN MEDICAL INC.: COMPANY SNAPSHOT
TABLE 111. B. BRAUN MEDICAL INC.: OPERATING SEGMENTS
TABLE 112. B. BRAUN MEDICAL INC.: PRODUCT PORTFOLIO
TABLE 113. B. BRAUN MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 115. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 116. OTSUKA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 117. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 118. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119. NEXGEN HEALTH: KEY EXECUTIVES
TABLE 120. NEXGEN HEALTH: COMPANY SNAPSHOT
TABLE 121. NEXGEN HEALTH: OPERATING SEGMENTS
TABLE 122. NEXGEN HEALTH: PRODUCT PORTFOLIO
TABLE 123. NEXGEN HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 124. JW LIFE SCIENCE CORPORATION: KEY EXECUTIVES
TABLE 125. JW LIFE SCIENCE CORPORATION: COMPANY SNAPSHOT
TABLE 126. JW LIFE SCIENCE CORPORATION: OPERATING SEGMENTS
TABLE 127. JW LIFE SCIENCE CORPORATION: PRODUCT PORTFOLIO
TABLE 128. JW LIFE SCIENCE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129. AMANTA HEALTHCARE LIMITED.: KEY EXECUTIVES
TABLE 130. AMANTA HEALTHCARE LIMITED.: COMPANY SNAPSHOT
TABLE 131. AMANTA HEALTHCARE LIMITED.: OPERATING SEGMENTS
TABLE 132. AMANTA HEALTHCARE LIMITED.: PRODUCT PORTFOLIO
TABLE 133. AMANTA HEALTHCARE LIMITED.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 134. BAXTER INTERNATIONAL INC.?: KEY EXECUTIVES
TABLE 135. BAXTER INTERNATIONAL INC.?: COMPANY SNAPSHOT
TABLE 136. BAXTER INTERNATIONAL INC.?: OPERATING SEGMENTS
TABLE 137. BAXTER INTERNATIONAL INC.?: PRODUCT PORTFOLIO
TABLE 138. BAXTER INTERNATIONAL INC.?: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION
FIGURE 2. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 3. SEGMENTATION INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 4. TOP INVESTMENT POCKET IN INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 11. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY SERVICE
FIGURE 12. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR IMMUNE BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR ENERGY BOOSTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR SKIN CARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MIGRAINE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY COMPONENT
FIGURE 18. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR NON-MEDICATED, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. GLOBAL INTRAVENOUS (IV) HYDRATION THERAPY MARKET SEGMENTATION, BY END USER
FIGURE 21. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOSPITAL CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR WELLNESS CENTERS SPAS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR HOME HEALTHCARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. INTRAVENOUS (IV) HYDRATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 29. COMPETITIVE DASHBOARD
FIGURE 30. COMPETITIVE HEATMAP: INTRAVENOUS (IV) HYDRATION THERAPY MARKET
FIGURE 31. TOP PLAYER POSITIONING, 2023
FIGURE 32. DAVITA: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. DAVITA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. DAVITA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. NIKKISO CO. LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. NIKKISO CO. LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. NIKKISO CO. LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. CORE IV THERAPY, LLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. CORE IV THERAPY, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. CORE IV THERAPY, LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. CRYOJUVENATE UK LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. CRYOJUVENATE UK LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. B. BRAUN MEDICAL INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. B. BRAUN MEDICAL INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. OTSUKA PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. OTSUKA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. NEXGEN HEALTH: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. NEXGEN HEALTH: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. NEXGEN HEALTH: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. JW LIFE SCIENCE CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. JW LIFE SCIENCE CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. AMANTA HEALTHCARE LIMITED.: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. AMANTA HEALTHCARE LIMITED.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 59. BAXTER INTERNATIONAL INC.?: NET SALES, 2021-2023 ($BILLION)
FIGURE 60. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 61. BAXTER INTERNATIONAL INC.?: REVENUE SHARE, BY REGION, 2023 (%)
